GSK to license Hutchmed’s dual-action cancer drug for $110M upfront
GSK licenses HUTCHMED's dual-action KRAS/EGFR cancer drug in a deal worth $110 million upfront plus milestones.
HUTCHMED
Private
HUTCHMED is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. The company has licensed its dual-action KRAS/EGFR cancer drug to GSK for $110 million upfront.
Company Info
Recent News
GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs
GSK acquires global rights to Hutchmed's Phase 1-ready antibody-targeted therapy conjugate for $110 million upfront, targeting lung, colorectal, and pancreatic cancers.